Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1468402

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1468402

In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2024-2032

PUBLISHED:
PAGES: 135 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3899
PDF & Excel (5 User License)
USD 4899
PDF & Excel (Corporate License)
USD 5899

Add to Cart

The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.

In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.

In-vivo CRO Market Trends:

The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.

Breakup by Type:

Rodent

Rats

Mice

Others

Non-Rodent

Breakup by GLP Type:

Non-GLP

In House

Outsourcing

GLP Toxicology

In House

Outsourcing

Breakup by Indication:

Autoimmune/Inflammation Conditions

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumor

Others

CNS Conditions

Epilepsy

Parkinson's Disease

Huntington's Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Diabetes

Obesity

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.

Key Questions Answered in This Report

  • 1. What was the size of the global in-vivo CRO market in 2023?
  • 2. What is the expected growth rate of the global in-vivo CRO market during 2024-2032?
  • 3. What are the key factors driving the global in-vivo CRO market?
  • 4. What has been the impact of COVID-19 on the global in-vivo CRO market?
  • 5. What is the breakup of the global in-vivo CRO market based on the type?
  • 6. What is the breakup of the global in-vivo CRO market based on the GLP type?
  • 7. What is the breakup of the global in-vivo CRO market based on indication?
  • 8. What are the key regions in the global in-vivo CRO market?
  • 9. Who are the key players/companies in the global in-vivo CRO market?
Product Code: SR112024A6267

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Rodent
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Rats
      • 6.1.2.2 Mice
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-Rodent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

  • 7.1 Non-GLP
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 In House
      • 7.1.2.2 Outsourcing
    • 7.1.3 Market Forecast
  • 7.2 GLP Toxicology
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 In House
      • 7.2.2.2 Outsourcing
    • 7.2.3 Market Forecast

8 Market Breakup by Indication

  • 8.1 Autoimmune/Inflammation Conditions
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Rheumatoid Arthritis
      • 8.1.2.2 Multiple Sclerosis
      • 8.1.2.3 Osteoarthritis
      • 8.1.2.4 Irritable Bowel Syndrome
      • 8.1.2.5 Others
    • 8.1.3 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Key Segments
      • 8.2.2.1 Chronic Pain
      • 8.2.2.2 Acute Pain
    • 8.2.3 Market Forecast
  • 8.3 Oncology
    • 8.3.1 Market Trends
    • 8.3.2 Key Segments
      • 8.3.2.1 Blood Cancer
      • 8.3.2.2 Solid Tumor
      • 8.3.2.3 Others
    • 8.3.3 Market Forecast
  • 8.4 CNS Conditions
    • 8.4.1 Market Trends
    • 8.4.2 Key Segments
      • 8.4.2.1 Epilepsy
      • 8.4.2.2 Parkinson's Disease
      • 8.4.2.3 Huntington's Disease
      • 8.4.2.4 Stroke
      • 8.4.2.5 Traumatic Brain Injury
      • 8.4.2.6 ALS
      • 8.4.2.7 Muscle Regeneration
      • 8.4.2.8 Others
    • 8.4.3 Market Forecast
  • 8.5 Diabetes
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Obesity
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Charles River Laboratories International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Evotec SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 ICON plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Iris Pharma (ABIONYX Pharma)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 North American Science Associates LLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Parexel International Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Pronexus Analytical AB
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Syneos Health
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
Product Code: SR112024A6267

List of Figures

  • Figure 1: Global: In-vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2023
  • Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2023
  • Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2023
  • Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
  • Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
  • Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vivo CRO Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: In-vivo CRO Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: In-vivo CRO Market Forecast: Breakup by GLP Type (in Million US$), 2024-2032
  • Table 4: Global: In-vivo CRO Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: In-vivo CRO Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: In-vivo CRO Market: Competitive Structure
  • Table 7: Global: In-vivo CRO Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!